Amphastar Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) on June 6, 2023, regarding events occurring on June 5, 2023. The report details the results of the Company's Annual Meeting of Stockholders, which was conducted virtually via live webcast.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results and does not contain financial performance data.
Material Changes and Voting Results
Stockholders voted on three proposals at the Annual Meeting. All proposals were approved, and the director nominees were elected. The specific voting results were as follows:
- Election of Directors: Three Class I directors were elected to serve until the 2026 annual meeting.
- Floyd F. Petersen: 28,274,102 For; 10,372,694 Against; 51,454 Abstained.
- Jacob Liawatidewi: 36,438,737 For; 2,218,750 Against; 40,763 Abstained.
- William J. Peters: 31,771,636 For; 6,883,199 Against; 43,415 Abstained.
- Ratification of Independent Auditor: Stockholders ratified the appointment of Ernst & Young LLP for the fiscal year ending December 31, 2023.
- 42,097,266 For; 585,099 Against; 45,457 Abstained.
- Executive Compensation (Advisory): Stockholders approved the compensation of named executive officers on an advisory basis.
- 37,281,658 For; 1,276,813 Against; 139,779 Abstained.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to reporting the outcome of the shareholder vote.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class I directors (Floyd F. Petersen, Jacob Liawatidewi, and William J. Peters) through the 2026 annual meeting.
- Confirm the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Note the significant number of "Against" votes for director Floyd F. Petersen (approximately 26.7% of votes cast excluding abstentions) compared to the other nominees.
- Review the Company's subsequent filings (e.g., 10-K or 10-Q) for financial performance data, as this 8-K contains no financial metrics.